Giuliano Caryl J, Freemantle Sarah J, Spinella Michael J
Department of Pharmacology and Toxicology, Dartmouth Medical School, and the Norris Cotton Cancer Center, Dartmouth Hitchcock-Medical Center, Hanover, NH 03755, USA.
Curr Cancer Ther Rev. 2006 Aug 1;2(3):255-270. doi: 10.2174/157339406777934681.
Treatment of testicular germ cell tumors (TGCTs) has been a success primarily due to the exquisite responsiveness of this solid tumor to cisplatin-based therapy. Despite the promise of cure for the majority of TGCT patients, the effectiveness of therapy for some patients is limited by toxicity and the problem of resistance. There is compelling rationale to further understand the biology of TGCTs in order to better treat other solid tumors and to address the shortcomings of present TGCT therapies. TGCTs contain undifferentiated pluripotent stem cells, known as embryonal carcinoma, that share many properties with human embryonic stem cells. The importance of cancer stem cells in the initiation, progression and treatment of solid tumors is beginning to emerge. We discuss TGCTs in the context of solid tumor curability and targeted cancer stem cell therapy.
睾丸生殖细胞肿瘤(TGCTs)的治疗已取得成功,这主要归功于这种实体瘤对基于顺铂的疗法具有极高的反应性。尽管大多数TGCT患者有望治愈,但部分患者的治疗效果受到毒性和耐药问题的限制。为了更好地治疗其他实体瘤并解决当前TGCT疗法的不足,深入了解TGCT的生物学特性具有令人信服的理由。TGCT含有未分化的多能干细胞,即胚胎癌,它与人类胚胎干细胞具有许多共同特性。癌症干细胞在实体瘤的发生、发展和治疗中的重要性正逐渐显现。我们在实体瘤可治愈性和靶向癌症干细胞治疗的背景下讨论TGCT。